Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fab'CD33-MORF1
- Development stage
- Preclinical
- Lead developer
- University of Utah
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fab'CD33-MORF1 is a tumor-targeting antibody fragment conjugate developed by the University of Utah as part of the Multi-Antigen T Cell Hybridizers (MATCH) platform. It consists of a Fab' fragment of an anti-CD33 monoclonal antibody covalently conjugated to a 25-base morpholino oligonucleotide (MORF1). Fab'CD33-MORF1 is designed to target CD33-expressing cancer cells, such as those in acute myeloid leukemia (AML) and multiple myeloma (MM). When administered alongside a complementary T-cell-engaging module, such as Fab'CD3-MORF2, the programmable hybridization between the complementary morpholino oligonucleotides (MORF1 and MORF2) brings the tumor cells and T cells into close proximity. This in situ post-assembly of the bispecific complex facilitates immune synapse formation and potent, antigen-dependent T-cell-mediated cytotoxicity while allowing for tunable cytokine release and reduced toxicity compared to conventional bispecific T-cell engagers.
- Other names
- Fab'-CD33-MORFFab'-CD33-MORF1Fab'CD33-MORF
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on Fab'CD33-MORF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fab'CD33-MORF1.